Trials / Terminated
TerminatedNCT03712787
An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)
An Extension Study of ABBV-8E12 in Early Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 364 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 57 Years – 88 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in participants with early AD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tilavonemab | solution for IV infusion |
Timeline
- Start date
- 2019-03-22
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2018-10-19
- Last updated
- 2022-09-22
- Results posted
- 2022-09-22
Locations
57 sites across 10 countries: United States, Australia, Belgium, Canada, Denmark, Finland, Italy, New Zealand, Spain, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03712787. Inclusion in this directory is not an endorsement.